FILING ANALYSIS · TUESDAY, NOVEMBER 17

Nuo Therapeutics, Inc. AURX — 8-K: Results of Operations and Financial Condition

positive

Nuo Therapeutics reported an 80% increase in total revenues for the third quarter 2026 and a 123% increase for the first nine months of 2026, with Aurix wound care revenues growing 17% sequentially, and received final funding of $325,000 under a loan agreement, but also incurred higher stock-based compensation and regulatory costs, and is prioritizing reaching operational breakeven and assessing o

The filing

8-K - Nuo Therapeutics, Inc. (0001091596) (Filer)

Read the filing on SEC EDGAR →

How we read impact: we grade every directional call in the open. Impact labels are AI estimates — not investment advice. See the full disclaimer.

Get filings like this every market day

The US SEC filings, UK RNS, EU notices, and Polymarket odds that matter — scored by AI, in one email.

Subscribe free →
All analyses · Earnings today · Latest brief · Track record
© 2026 Dutchcode B.V. · Built by
Blinkof.ai verified — grade A+